Abstract
Vaccine development is essential for pandemic preparedness. We previously conducted a Phase 1 clinical trial of the vector vaccine candidate MVA-MERS-S against the Middle East respiratory syndrome coronavirus (MERS-CoV), expressing its full spike glycoprotein (MERS-CoV-S), as a homologous two-dose regimen (Days 0 and 28). Here, we evaluate a third vaccination with MVA-MERS-S in a subgroup of trial participants one year after primary immunization. A booster vaccination with MVA-MERS-S is safe and well-tolerated. Both binding and neutralizing anti-MERS-CoV antibody titers increase substantially in all participants and exceed maximum titers observed after primary immunization more than 10-fold. We identify four immunogenic IgG epitopes, located in the receptor-binding domain (RBD, n=1) and the S2 subunit (n=3) of MERS-CoV-S. The level of baseline anti-human coronavirus antibody titers does not impact the generation of anti-MERS-CoV antibody responses. Our data support the rationale of a booster vaccination with MVA-MERS-S and encourage further investigation in larger trials.
One Sentence Summary A late booster vaccination with the vector vaccine MVA-MERS-S against MERS-CoV is safe and significantly increases humoral immunogenicity including responses to four IgG epitopes.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT03615911
Funding Statement
This research was supported by the German Center for Infection Research (DZIF), grant numbers FKZ8009801908, FKZ8009701702, FKZ8033801809 (section emergency vaccines) and FKZ8033701711 (infrastructure animal facility). AF received a DZIF Clinical Leave Grant, grant number FKZ80095CLANF. CDr was supported by the German Ministry of Research and Education (BMBF) BMBF-RAPID 01KI1723A. VMC was supported by BMBF project VARIPath (01KI2021). FFL was supported by the German Federal Ministry of Education and Research grant 13XP5050A and the MPG-FhG cooperation grant Glyco3Display. The funder of this publicly-funded investigator-initiated trial had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Competent National Authority (Paul-Ehrlich-Institute) and the Ethics Committee of the Hamburg Medical Association. The trial was conducted as an investigator-initiated trial under the sponsorship of the University Medical Center Hamburg-Eppendorf (Hamburg, Germany) in accordance with ICH-GCP and is registered at ClinicalTrials.gov NCT03615911, EudraCT No. 2014-003195-23, PVN5531. The observational study was registered with and approved by the Ethics Committee of the Hamburg Medical Association (Protocol No. PV4780).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Data Availability
All data associated with this study are in the manuscript or the Supplementary Materials. Deidentified participant data collected during the trial can be shared through a data or materials transfer agreement.